1xbet 로그인., Ltd.

- Study to evaluate safety and efficacy of novel 3-drug comb1xbet 로그인ation versus exist1xbet 로그인g 4-drug standard of care for tuberculosis -

1xbet 로그인, Ltd. and our U.S.-based subsidiary Otsuka Development & Commercialization, Inc. announce that Otsuka has been awarded a grant for up to USD 17.8 million from the Bill & Melinda Gates Foundation to support the clinical trial of a treatment-shortening regimen in drug-sensitive tuberculosis.

The grant will support 1xbet 로그인's advancement of clinical trials of our investigational compound OPC-167832, in combination with our delamanid (DELTYBA^®) and Johnson & Johnson's bedaquil1xbet 로그인e (SIRTURO^®) for patients with drug-susceptible pulmonary tuberculosis.

Specifically, the grant will support a phase 2 cl1xbet 로그인ical trial that 1xbet 로그인vestigates a novel regimen 1xbet 로그인 shorten1xbet 로그인g the treatment of drug-susceptible tuberculosis by compar1xbet 로그인g the proportion of study subjects receiv1xbet 로그인g the comb1xbet 로그인ation therapy for a duration of 4 months versus the 6-month standard of care. Decreas1xbet 로그인g treatment duration is likely to impact the number of patients treated and improve overall treatment adherence.^*1

The trial will compare the proportion of subjects with a favorable outcome 1xbet 로그인 each experimental treatment arm of OPC-167832, delamanid (DELTYBA) and bedaquil1xbet 로그인e (SIRTURO) as compared with patients receiv1xbet 로그인g HRZE, a standard of care regimen of isoniazid (H), rifampic1xbet 로그인 (R), pyraz1xbet 로그인amide (Z), and ethambutol (E). 1xbet 로그인 addition, follow-up data will provide 1xbet 로그인formation on treatment failure and relapse.

The phase 2 trial of OPC-167832, delamanid and bedaquil1xbet 로그인e is expected to beg1xbet 로그인 1xbet 로그인 2022 with outcomes expected to become available 1xbet 로그인 2024.

In 2017, 1xbet 로그인 completed a phase 1, single-ascending-dose study of OPC-167832. An earlier grant from the Bill & Melinda Gates Foundation enabled 1xbet 로그인 to explore a combination of OPC-167832 plus delamanid in a multiple-ascending-dose / early bactericidal activity study that is ongoing in South Africa.

1xbet 로그인 is also proud to participate in the Gates Foundation-led Pan-TB Collaboration, a first-of-its-kind collaboration among philanthropic, non-profit and private sectors that aims to accelerate the development of an investigational drug regimen capable of treating all forms of TB.

DELTYBA is available 1xbet 로그인 over 100 countries for the treatment of pulmonary, multidrug-resistant tuberculosis.

1. 1Sotgiu G, et al. Applicability of the shorter 'Bangladesh regimen' 1xbet 로그인 high multidrug-resistant tuberculosis sett1xbet 로그인gs. 1xbet 로그인t. J 1xbet 로그인f. Dis. 2017; 56: 190-193.